Omalizumab biosimilar (IBC Generium)

奥马佐单抗生物类似药 (IBC Generium)

Report date: 2022/02/22 15:21:08

Base Information

Drug NameOmalizumab biosimilar (IBC Generium)
Drug Alias Name奥玛利珠单抗生物仿制药 (IBC Generium)奥马珠单抗生物仿制药 (IBC Generium)奥马佐单抗生物仿制药 (IBC Generium)GenolairGNR-044
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunoglobulin E inhibitors
TargetsImmunoglobulin E
Therapy Area/IndicationsChronic UrticariaAsthma
Global Approved IndicationsChronic UrticariaAsthma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2022/02/09
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesIbc Generium
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsChronic UrticariaAsthma
Inactive IndicationsN/A

Other Information

ATC CodeR03DX05
Related LinksN/A